Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines

Journal of Infectious Diseases

Volumn 174, Issue 2, 1996, Pages 387-392

  Wang, Jian Ben ^b   Adler, Stuart P ^a   Hempfling, Sue ^b   Burke, Rae Lyn ^b   Duliège, Anne Marie ^b   Starr, Stuart E ^b   Plotkin, Stanley A ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOMEGALOVIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G; LIVE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; SECRETORY IMMUNOGLOBULIN; VIRUS GLYCOPROTEIN;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN EXPERIMENT; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MUCOSA; NORMAL HUMAN; NOSE SMEAR; PRIORITY JOURNAL; SALIVA LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 19144372367     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.2.387     Document Type: Article

References (15)

1. Stagno S, Pass RF, Cloud G, et al. Primary CMV infection in pregnancy, incidence, transmission to fetus, and clinical outcome. JAMA 1986;256:1904-8.
2. Adler SP. Molecular epidemiology of cytomegalovirus: a study of factors affecting transmission among children at three day-care centers. Pediatr Infect Dis J 1991;10:584-90.
3. Adler SP. Cytomegalovirus and child day-care: risk factors for maternal infection. Pediatr Infect Dis J 1991;10:590-4.
4. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by a primary cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.
5. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98.
6. Plotkin SA, Farquhar J, Hornberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 1976;134:470-5.
7. Spaete RR, Saxena A, Scott PI, et al. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol 1990;64:2922-31.
8. Adler SP, McVoy M. Detection of cytomegalovirus antibody by enzyme immunoassay and lack of evidence for and effect resulting from strain heterogeneity. J Clin Microbiol 1986;24:870-2.
9. Schaefer ME, Rhodes M, Prince S, Michalek SM, McGhee JR. A plastic intraoral device for the collection of human parotid saliva. J Dent Res 1977;56:728-33.
10. Draper N, Smith H. The matrix approach to linear regression. In: Applied regression analysis. 2nd ed. New York: John Wiley & Sons, 1981:70-136.
11. O'Shea S, Best JM, Bantvala JE, Shepherd WM. Development and persistence of class-specific antibodies in the serum and nasopharyngeal washings of rubella vaccinees. J Infect Dis 1985;151:89-98.
12. Zhaori G, Sun M, Faden HS, Ogra PL. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 1989;159:1018-24.
13. Russell MW, Mestecky J. Induction of the mucosal immune response. Rev Infect Dis 1988;10(suppl):S440-6.
14. Kauppi M, Eskola J, Käyhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus inflitenzae type b capsular conjugate vaccines. Pediatr Infect Dis J 1995;14:286-94.
15. Shen CY, Chang SF, Chao MF, Huang ES, Wu CW. Identification of a serial change in recurrent cylomegalovirus strains in a healthy child by polymerase chain reaction. J Infect Dis 1993;168:252-3.